ReviewLeukemia2014
Should persons with acute myeloid leukemia have a transplant in first remission?
Review in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia.Leukemia · 2016Trial
- Allogeneic transplantation in acute myelogenous leukemia: a comprehensive single institution's experience.Haematologica · 2023Article
- Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT.Blood cancer journal · 2021Article
- Article
- Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia.Current treatment options in oncology · 2018Review
- Precision oncology for acute myeloid leukemia using a knowledge bank approach.Nature genetics · 2017Article
- Valproic acid may exerts its cytotoxic effect through rassf1a expression induction in acute myeloid leukemia.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Commentary: How do haematopoietic cell transplants cure leukaemia?International journal of hematology · 2016Article
- Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012.Leukemia · 2016Article
- Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors.Oncotarget · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite more than 40 years of extensive study, it remains uncertain which individuals, if any, with acute myelogenous leukemia (AML) in first remission should receive a blood cell or bone marrow transplant versus post-remission chemotherapy (or both). Nevertheless, there is a recent trend toward recommending more transplants in this setting. We consider four myths underlying this recommendation: (1) only individuals achieving second remission benefit from a transplant; (2) there is no effective therapy for relapse other than an allotransplant; (3) we can accurately predict which individuals with AML in first remission need a transplant; and (4) detection of minimal residual disease in first remission will resolve this controversy. We discuss these misconceptions and suggest approaches to resolve this issue.
Indexed as
Identifiers
24727674What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.